News articles about WAVE Life Sciences (NASDAQ:WVE) have trended somewhat positive on Wednesday, according to Accern. The research group identifies positive and negative news coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. WAVE Life Sciences earned a news impact score of 0.11 on Accern’s scale. Accern also assigned press coverage about the company an impact score of 47.3608552631586 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
Here are some of the news headlines that may have impacted Accern Sentiment Analysis’s rankings:
- Brokers Set Expectations for WAVE Life Sciences’ Q2 2018 Earnings (WVE) (americanbankingnews.com)
- Q2 2018 EPS Estimates for WAVE Life Sciences Cut by Leerink Swann (WVE) (americanbankingnews.com)
- WAVE Life Sciences (WVE) Expected to Announce Quarterly Sales of $6.59 Million (americanbankingnews.com)
- FY2022 Earnings Estimate for WAVE Life Sciences (WVE) Issued By Leerink Swann (americanbankingnews.com)
- WAVE Life Sciences (WVE) Posts Earnings Results, Misses Expectations By $0.36 EPS (americanbankingnews.com)
WVE has been the subject of several recent research reports. ValuEngine raised shares of WAVE Life Sciences from a “sell” rating to a “hold” rating in a research report on Thursday, April 12th. Mizuho upped their target price on shares of WAVE Life Sciences from $34.00 to $65.00 and gave the company a “buy” rating in a research note on Monday, March 19th. Leerink Swann dropped their price objective on shares of WAVE Life Sciences from $64.00 to $62.00 and set an “outperform” rating for the company in a research note on Tuesday, March 13th. SunTrust Banks increased their price objective on shares of WAVE Life Sciences to $60.00 and gave the company a “buy” rating in a research note on Friday, March 9th. Finally, BidaskClub cut shares of WAVE Life Sciences from a “strong-buy” rating to a “buy” rating in a research report on Saturday, March 3rd. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and six have given a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus price target of $53.40.
WAVE Life Sciences (NASDAQ:WVE) last released its earnings results on Wednesday, May 9th. The company reported ($1.26) earnings per share for the quarter, missing the consensus estimate of ($0.90) by ($0.36). WAVE Life Sciences had a negative net margin of 2,613.03% and a negative return on equity of 76.93%. The firm had revenue of $1.42 million during the quarter, compared to the consensus estimate of $6.59 million. analysts predict that WAVE Life Sciences will post -4.78 EPS for the current fiscal year.
In other news, insider Chris Francis sold 21,639 shares of the company’s stock in a transaction that occurred on Tuesday, February 20th. The stock was sold at an average price of $55.40, for a total value of $1,198,800.60. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Paul Bolno sold 18,289 shares of the company’s stock in a transaction that occurred on Wednesday, May 2nd. The shares were sold at an average price of $45.00, for a total value of $823,005.00. The disclosure for this sale can be found here. In the last ninety days, insiders sold 40,755 shares of company stock valued at $2,064,813. 53.00% of the stock is owned by insiders.
About WAVE Life Sciences
Wave Life Sciences Ltd., a biotechnology company, designs, develops, and commercializes nucleic acid therapeutic candidates for genetically defined diseases by utilizing proprietary synthetic chemistry drug development platform. The company is primarily developing oligonucleotides that target genetic defects to either reduce the expression of disease-promoting proteins or transform the production of dysfunctional mutant proteins into the production of functional proteins.
Receive News & Ratings for WAVE Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for WAVE Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.